The action is self-limiting as when the increased insulin release reduces plasma glucose, the ability of GLP-1 to act is turned off (44)
Individuals taking GLP-1 medications should consult their prescribing provider before beginning any new treatment protocol
The phase 2 trial showed 22.8% average weight loss at 48 weeks with the 8mg dose, only 1.4 percentage points less than the 12mg dose
Theres no monthly membership fee
2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (NCT07321886)